We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Anticancer Therapies – Products

Optimize Cell and Gene Therapies With Single-Cell Multiomics content piece image
App Note / Case Study

Optimize Cell and Gene Therapies With Single-Cell Multiomics

One of the more promising types of cancer immunotherapy involves engineering immune cells to recognize and attack cancer.
Generating Cell Repellent Surfaces in Microfluidic Devices content piece image
Product News

Generating Cell Repellent Surfaces in Microfluidic Devices

AMSBIO report that researchers from the Medical University of Vienna (Austria), have used Lipidure® - CM5206 to coat channels in their novel microfluidic devices, to prevent cell adhesion.
Phenotypic and Functional Characterization of CAR-T Cells content piece image
Whitepaper

Phenotypic and Functional Characterization of CAR-T Cells

The successful use of immunotherapies to help combat cancer has expanded rapidly in the last few years, with many therapies now approved for clinical use.
Whitepaper

Accelerating Cancer Immune Cell Therapies

As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life.
Novel Assay Platform for 3D Microfluidic Cancer Research content piece image
Product News

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.
Accurate Quantification of Interferon Gamma Across Immunoassay Platforms content piece image
App Note / Case Study

Accurate Quantification of Interferon Gamma Across Immunoassay Platforms

Download this app note to discover immunoassay platforms that are consistent for your cell therapy and immunology development needs.
Synthetic Immune Recruitment – A New Way To Fight Tumors content piece image
Product
Advertisement

Synthetic Immune Recruitment – A New Way To Fight Tumors

The utility and efficiency of the Octet® platform at characterizing covalent immune recruiter molecule function and their efficacy as modulators of protein proximity was demonstrated. Efficient in vitro validation further enables the potential acceleration of CIR translation to in vivo model validation and the clinic as a new class of synthetic tumor immunotherapeutic.
Autologous CAR T-Cell Manufacturing content piece image
Whitepaper

Autologous CAR T-Cell Manufacturing

Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced from preclinical research. This success has driven an influx of companies to further develop CAR T-cell constructs to make them more effective, safe and persistent.
Protein Biomarkers Show Promise in Predicting Patient Response to Cancer Immunotherapies content piece image
Whitepaper

Protein Biomarkers Show Promise in Predicting Patient Response to Cancer Immunotherapies

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy.
Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial content piece image
Product News

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial

Avacta Group plc is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.
Advertisement